7 Products Boston Scientific is Betting on in 2014: Synergy Drug-Eluting Stent

Posted in Cardiovascular by Jamie Hartford on February 4, 2014

Synergy Drug-Eluting Stent

The Synergy Everolimus-Eluting Platinum Chromium Coronary Stent System, which was CE Marked in October 2012, is unique in that its bioresorbable polymer and drug coating dissipate in just three months, according to Boston Scientific. A limited launch in Europe brought good results, and this year the company hopes to expand the launch of the Synergy stent, which is priced at a premium, throughout the EU supported by a clinical evaluation portfolio with 28,000 patients, Mahoney said.

Premier Watchman




[image courtesy of BOSTON SCIENTIFIC]

Printer-friendly version
No votes yet

Login to post comments